The Search for Biomarkers in Metastatic Breast Cancer

Video

In Partnership With:

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

James M. Reuben, PhD, MBA, a professor in the Department of Hematopathology at The University of Texas MD Anderson Cancer Center, discusses the search for biomarkers in patients with metastatic breast cancer.

Reuben’s lab searches for biomarkers in patients with cancer, specifically patients with inflammatory breast cancer and breast cancer in general. Biomarkers are defined based on the clinical trial being conducted and tailored to the target being examined, explains Reuben. In one study, patients with triple-negative breast cancer who had stable disease were treated with an anti—PD-1 agent to see if responses could be prolonged in a maintenance trial, says Reuben.

Blood samples are used over tissue samples because, in a metastatic situation, repeat biopsies are not possible using tissue. Looking at biomarkers in the peripheral blood might be useful to monitor patients, stratify them, and see if they are benefitting from therapies, concludes Reuben.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,